APRINOIA Therapeutics Inc. – Trademark Portfolio

Entity Type: 03

APRINOIA Therapeutics Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. Currently, 4 trademarks are registered. Notable registered marks include PIXATAU, TAUCISE, TAUCIFIC, and TAUCISIVE. The owner is based in Tokyo.

Shinkawa 1-2-8, Chuo-ku

Tokyo 104-0033 , JP

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

TAUCISIVE
TAUCISIVE
Registered 2021
TAUCIFIC
TAUCIFIC
Registered 2021
PIXATAU
PIXATAU
Registered 2021
TAUCISE
TAUCISE
Registered 2021
TAUNEURO
TAUNEURO
Abandoned 2021

Trademark Classifications

APRINOIA Therapeutics Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does APRINOIA Therapeutics Inc. have?

APRINOIA Therapeutics Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 abandoned.

What trademark classes does APRINOIA Therapeutics Inc. file in?

APRINOIA Therapeutics Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are APRINOIA Therapeutics Inc.'s most well-known trademarks?

APRINOIA Therapeutics Inc.'s registered trademark portfolio includes well-known marks such as PIXATAU, TAUCISE, TAUCIFIC, and TAUCISIVE. These are among 4 currently registered trademarks in the portfolio.

What is APRINOIA Therapeutics Inc.'s trademark registration success rate?

APRINOIA Therapeutics Inc. has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.